Panelists discuss how clear cell renal cell carcinoma (RCC) represents the most common kidney cancer subtype, typically affecting men in their 50s and...

Panelists discuss how the CheckMate 214 study demonstrated durable overall survival benefits with ipilimumab plus nivolumab vs sunitinib, with 9-year...

An oncologist’s passion for breast surgery, novel cancer vaccines in gastrointestinal cancers, and emerging actionable biomarkers for lung cancer were...

The addition of dendritic cells to TACE in patients with intermediate-stage HCC did not significantly increase the incidence or severity of AEs.

Boris M. Kiselev, MD, discusses the role of psycho-oncology in comprehensive cancer care, addressing barriers and offering a vision for the field’s fu...

Boris M. Kiselev, MD, provides practical advice for oncology clinicians on how to approach and initiate conversations about a patient’s mental and emo...

Current research initiatives in the kidney cancer field include exploring anti–PD-1, anti–LAG-3, and anti–CTLA-4 combination regimens.

Results from the monarchE study showed a statistically significant OS improvement with abemaciclib plus ET for patients with HR+/HER2– early breast ca...

Discover key takeaways on tumor markers, the BEP vs. EP debate, and the role of surgery in stage II testicular cancer.

TT125-802 monotherapy shrank the tumors in 5 of 7 patients with drug-resistant NSCLC, and no thrombocytopenia was observed.